Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with ...

Multiple Sclerosis cases are rising in India, especially among women, with experts stressing early diagnosis, access to ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...

Early diagnosis and treatment aim to minimise the impact of multiple sclerosis on their daily lives and extend their ...

The initial proceeds to Immunic from the offering were approximately $65 million, before deducting underwriting discounts and commissions and offering expenses. The Company may receive up to an ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The NHS has warned about potential symptoms of an incurable condition that profoundly affects the central nervous system.

Using disease-modifying therapies in MS tends to reduce the risk of stroke, though effects vary depending on the type of DMT, ...

Around 150,000 people are living with the condition in the UK, while a further 7,100 are newly diagnosed each year ...